Sequential immunopathologic study of oral lichen planus treated with tretinoin and etretinate.
Twenty-five patients with oral lichen planus confirmed by histologic examination were divided into three groups: 10 patients received topical treatment with tretinoin, 10 received systemic treatment with etretinate, and the five remaining patients, who received no treatment, served as a control group. An immunopathologic study with the use of monoclonal antibodies was carried out before and after the 3-month course of treatment and showed a variation in the distribution and phenotype of inflammatory cells. No difference between the two types of treatment was observed, but treated patients had a shorter evolution of the disease when compared with control patients.
Baudet-Pommel
M
M
Department of Oral Pathology, School of Dentistry, Clermont-Ferrand, France.
Janin-Mercier
A
A
Souteyrand
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D017252:CD3 Complex; D015704:CD4 Antigens / Q000032:analysis; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D016827:CD8 Antigens; D005050:Etretinate / Q000008:administration & dosage*; D005260:Female; D006684:HLA-DR Antigens / Q000032:analysis; D006801:Humans; D007958:Leukocyte Count; D008010:Lichen Planus / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009059:Mouth Diseases / Q000188:drug therapy* / Q000276:immunology*; D011948:Receptors, Antigen, T-Cell / Q000032:analysis; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects; D014212:Tretinoin / Q000008:administration & dosage*
D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D015704:CD4 Antigens; D016827:CD8 Antigens; D006684:HLA-DR Antigens; D011948:Receptors, Antigen, T-Cell; D014212:Tretinoin; D005050:Etretinate